Leslie M. Shaw, PhD

Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Clinical Toxicology Laboratory
University of Pennsylvania Perelman School of Medicine

Contact InformationHospital of the University of Pennsylvania
7.103 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529


Specialty Division

Laboratory Medicine

Research Expertise

Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42) and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.

Clinical Expertise

Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.

Other Expertise

Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including 25-OH vitamin D.


B.S. (Cum Laude, Chemistry), LeMoyne College, Syracuse, New York, 1962
Ph.D. (Biochemistry), S.U.N.Y. at Upstate Medical Center, 1968

Specialty Certification

American Board of Clinical Chemistry, 1973
American Board of Clinical Chemistry in Toxicological Chemistry, 1990
USC School of Medicine, Laboratory of Applied Pharmacokinetics, 1995

Postgraduate Training

NIH Post doctoral Fellowship Department of Molecular Biology, The Johns Hopkins University, Baltimore, MD, 1968-1970
Fellow, Neuroscience Research Program, 1969-1969
NIH Postdoctoral Fellowship, William Pepper Laboratories, Hospital of the University of Pennsylvania, Philadelphia, PA, 1970-1972

Awards and Honors

Norman Kubasik Lectureship Award, Upstate New York AACC Meeting, 1992-1992
Outstanding Speaker Award, 1995, 1996, 1997, 2000, 2001, 2002, 2003, American Association for Clinical Chemistry, 1995-2003
Reinhold Award, Philadelphia Section, AACC, 1995-1995
The Peter C Nowell Teaching Award, University of Pennsylvania Medical Center, 1999-1999
IATDMCT Charles Pippenger Award for Outstanding Contributions in Therapeutic Drug Monitoring, 1999-1999
The Kevin Salhany, MD, Award for Excellence in Clinical Teaching; Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, 2005-2005
LeMoyne College - Distinguished Alumni Award, 2012-2012
AACC Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine., 2013

Memberships and Professional Organizations

Alpha Sigma Nu, National Jesuit Honor Society, 1962 - 1964
American Chemical Society, 1962 - present
American Association for Clinical Chemistry, 1972 - present
Philadelphia Section, American Association for Clinical Chemistry: 1996 (Program Chairman).
Philadelphia Section, American Association for Clinical Chemistry: 1978, 1978 - Present
Philadelphia Section, American Association for Clinical Chemistry:, 1978 - Present
American Association for the Advancement of Science, 1978 - present
International Federation of Clinical Chemistry, 1979 - present
AACC/NACB Task Force on Cyclosporine Monitoring, 1985 - 1987
National Academy of Clinical Biochemistry:, 1986 - present
International Association for Therapeutic Drug Monitoring and Clinical Toxicology, 1989 - present
American Society for Mass Spectroscopy, 1991 - 1994
Therapeutic Drug Monitoring and Clinical Toxicology Division of the AACC:, 1991 - Present
USP Council of Experts,, 2001 - 2002
Society of Toxicology, 2004 - 2007, 2004 - 2007
Alzheimers Association, 2005 - Present
Alzheimers Association Global Biomarker Standardization Consortium., 2011 - Present
Eli Lilly, 2011 - Present
Roche (Member of Scientific Advisory Board), 2016 - Present
Cerebrospinal Fluid appropriate Use, Criteria Workgroup, Alzheimers Association., 2017 - Present

Selected Publications

CSF biomarkers of Alzheimer’s disease concord with amyloid-B PET and predict clinical progression: A study of fully-automated immunoassays in BioFINDER and ADNI cohorts.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM., Alz and Dementia - In Press., 2018 - In Press

Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease.

Phillips JS, Da Re F, Dratch L, Xie SX, Irwin DJ, McMillan CT, Vaishnavi SN, Ferrarese C, Lee EB, Shaw LM, Trojanowski JQ, Wolk DA, Grossman M., Neurobiology of Aging. 63(): , 2018 - In Press

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S and Zhang J., Neurology. 90(2): , 2018

CSF Tau and Amyloid-Beta Predict Cerebral Synucleinopathy in Autopsied Lewy Body Disorders.

Irwin DJ, Sharon X Xie, Coughlin D, Nevier N, Akhtar R, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A, Duda JE, Spindler M, Siderowf A, Hurtig HI, Shaw LM, Grossman M,and Trojanowski JQ., Neurology. 90(): 1-9, 2018

Cerebrospinal Fluid, Plasma, and saliva in the BioFIND Study: Relationships among biomarkers and Parkinson's disease features.

Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Dain-Hilaire M-H, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fischer C, Gwinn K, Kang UJ., Movement Disorders. 33(2): 282-88, 2018

Metabolic network failures in Alzheimer's disease - A biochemical road map.

Toledo JB, Arnold M, Kastenmüller G, Chang R, Baillie RA, Han X, Thambisetty M, Tenenbaum JD, Suhre K, Thompson JW, St. John-Williams L, MahmoudianDehkordi S, Rotroff DM, Jack JR, Motsinger-Reif A, Risacher SL, Blach C, Lucas JE, Massaro T, Louie G, Zhu H, Dallmann G, Klavins K, Koal T, Kim S, Nho K, Shen L, Casanova R, Varma S, Legido-Quigley C, Moseley MA, Zhu K, Henrion MYR, van der Lee SJ, Harms AC, Demirkan A, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Saykin AJ, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R, for the Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium., Alzheimer's & Dementia. 13(9): 965-984, 2017

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson Disease.

Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu I-W, Zhang Y, Nalls M, Singleton A, Shaw LM, Kang J-H, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D, and The Parkinson's Progressive Markers Initiative (PPMI)., PLOS One 12(5): 1-18, 2017

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack Jr CR, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, etal., The World J of Biol Psych., 2017

Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.

Deters KD, Risacher SL, Kim S, Nho K, West JD, Blennow K, Zetterberg H, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ for the Alzheimer Disease Neuroimaging Initiative., Journal of Alzheimer's Disease. 58(): 1245-1254, 2017

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.

Arneric SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L, Dean R, Engelborghs S, Genius J, Gordon MF, Hitchcock J, Kaplow J, Luthman J, Meibach R, Raunig D, Romero K, Samtani MN, Savage M, Shaw LM, Stephenson D, Umek RM, Vanderstichele H, Willis B, Yule S., J Alzheimers Disease. 55(): 19-35, 2017